###begin article-title 0
IKKalpha, a critical regulator of epidermal differentiation and a suppressor of skin cancer
###end article-title 0
###begin p 1
This is an open-access article distributed under the terms of the Creative Commons Attribution Licence, which permits distribution, and reproduction in any medium, provided the original author and source are credited. This licence does not permit commercial exploitation or the creation of derivative works without specific permission.
###end p 1
###begin p 2
###xml 375 378 347 350 <italic>Ikk</italic>
###xml 383 386 351 354 <sup>&#8211;/&#8211;</sup>
###xml 515 530 483 498 <italic>stratum corneum</italic>
###xml 532 535 500 503 <italic>Ikk</italic>
###xml 387 391 <span type="species:ncbi:10090">mice</span>
IkappaB kinase alpha (IKKalpha), one of the two catalytic subunits of the IKK complex involved in nuclear factor kappaB (NF-kappaB) activation, also functions as a molecular switch that controls epidermal differentiation. This unexpected function requires IKKalpha nuclear translocation but does not depend on its kinase activity, and is independent of NF-kappaB signalling. Ikkalpha-/- mice present with a hyperproliferative and undifferentiated epidermis characterized by complete absence of a granular layer and stratum corneum. Ikkalpha-deficient keratinocytes do not express terminal differentiation markers and continue to proliferate even when subjected to differentiation-inducing stimuli. This antiproliferative function of IKKalpha is also important for the suppression of squamous cell carcinogenesis. The exact mechanisms by which nuclear IKKalpha controls keratinocyte proliferation and differentiation remained mysterious for some time. Recent studies, however, have revealed that IKKalpha is a major cofactor in a TGFbeta-Smad2/3 signalling pathway that is Smad4 independent. This pathway controls cell cycle withdrawal during keratinocyte terminal differentiation. Although these are not the only functions of nuclear IKKalpha, this multifunctional protein is a key regulator of keratinocyte and epidermal differentiation and a critical suppressor of skin cancer.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 395 416 395 416 <xref ref-type="bibr" rid="b15">Fuchs and Byrne, 1994</xref>
###xml 418 439 418 439 <xref ref-type="bibr" rid="b34">Koster and Roop, 2007</xref>
###xml 533 536 533 536 <italic>p63</italic>
###xml 746 751 734 739 <italic>et al</italic>
###xml 740 757 728 745 <xref ref-type="bibr" rid="b2">Candi <italic>et al</italic>, 2007</xref>
###xml 766 771 754 759 <italic>et al</italic>
###xml 759 777 747 765 <xref ref-type="bibr" rid="b33">Koster <italic>et al</italic>, 2007</xref>
###xml 953 974 941 962 <xref ref-type="bibr" rid="b34">Koster and Roop, 2007</xref>
###xml 1018 1043 1006 1031 <xref ref-type="bibr" rid="b43">M'Boneko and Merker, 1988</xref>
###xml 1241 1252 1229 1240 <xref ref-type="bibr" rid="b70">Smart, 1970</xref>
###xml 1254 1279 1242 1267 <xref ref-type="bibr" rid="b78">Weiss and Zelickson, 1975</xref>
###xml 1406 1417 1394 1405 <xref ref-type="bibr" rid="b70">Smart, 1970</xref>
###xml 1419 1440 1407 1428 <xref ref-type="bibr" rid="b34">Koster and Roop, 2007</xref>
###xml 1606 1627 1594 1615 <xref ref-type="bibr" rid="b34">Koster and Roop, 2007</xref>
###xml 1735 1756 1723 1744 <xref ref-type="bibr" rid="b16">Fuchs and Green, 1980</xref>
###xml 2088 2093 2076 2081 <italic>et al</italic>
###xml 2082 2099 2070 2087 <xref ref-type="bibr" rid="b3">Candi <italic>et al</italic>, 2005</xref>
###xml 2162 2177 2150 2165 <italic>stratum corneum</italic>
###xml 2328 2333 2316 2321 <italic>et al</italic>
###xml 2322 2339 2310 2327 <xref ref-type="bibr" rid="b3">Candi <italic>et al</italic>, 2005</xref>
###xml 2341 2352 2329 2340 <xref ref-type="bibr" rid="b64">Segre, 2006</xref>
###xml 2359 2374 2347 2362 <italic>stratum corneum</italic>
###xml 2438 2449 2426 2437 <xref ref-type="bibr" rid="b11">Elias, 2004</xref>
###xml 2451 2462 2439 2450 <xref ref-type="bibr" rid="b64">Segre, 2006</xref>
###xml 2517 2522 2505 2510 <italic>et al</italic>
###xml 2509 2528 2497 2516 <xref ref-type="bibr" rid="b23">Hardman <italic>et al</italic>, 1998</xref>
###xml 214 219 <span type="species:ncbi:10090">mouse</span>
###xml 522 527 <span type="species:ncbi:10090">mouse</span>
###xml 1117 1122 <span type="species:ncbi:10090">mouse</span>
###xml 2502 2507 <span type="species:ncbi:10090">mouse</span>
The epidermis, the outermost part of the skin, is a stratified and keratinized squamous epithelium mainly composed of keratinocytes, which forms a protective barrier. Epidermal differentiation, which starts in the mouse at embryonic day (E) 12, leads to formation of several distinct cell layers characterized by their ultrastructure, mitotic state and expression of specific molecular markers (Fuchs and Byrne, 1994; Koster and Roop, 2007). The basal layer develops from the surface ectoderm at approximately E9.5 in the mouse. The p63 gene, which specifies different isoforms of a transcription factor related to tumour suppressor p53, controls basal layer formation and maintenance as well as IkappaB kinase alpha (IKKalpha) expression (Candi et al, 2007; Koster et al, 2007). Basal keratinocytes, including epidermal stem cells and transit-amplifying cells, are cuboidal, express cytokeratins (CKs) 5 and 14 and have a high proliferative potential (Koster and Roop, 2007). These cells form the embryonic periderm (M'Boneko and Merker, 1988), which is lost on establishment of the epidermal barrier. At E12 in the mouse, the basal cells give rise to the intermediate cell layer located between the embryonic basal layer and the periderm (Smart, 1970; Weiss and Zelickson, 1975). The intermediate cells divide several times before they withdraw from cell cycle and mature into postmitotic spinous cells (Smart, 1970; Koster and Roop, 2007). By contrast, adult basal keratinocytes directly become spinous cells when terminal differentiation is initiated, without involvement of an intermediate cell type (Koster and Roop, 2007). The spinous layer is characterized by a switch in keratin expression, from CK5 and CK14 to CK1 and CK10 (Fuchs and Green, 1980). Involucrin, a marker of early terminal differentiation is also synthesized in the upper part of this layer. The spinous cells continue their differentiation and maturation to form the granular layer, which is characterized by keratohyalin granules and expression of the late differentiation markers loricrin and filaggrin (Candi et al, 2005). Terminal differentiation gives rise to the cornified layer (stratum corneum), which consists of extremely flat, keratin-filled and anucleated keratinocytes, called corneocytes, which are mummified within a lipid matrix (Candi et al, 2005; Segre, 2006). The stratum corneum is primarily responsible for the barrier function of the skin (Elias, 2004; Segre, 2006), which is established around E17.5 in mouse (Hardman et al, 1998). Although major progress has been made in understanding the molecular changes that characterize epidermal differentiation, less is known about the signalling pathways that control these events. Here, we provide an overview of the current understanding of the central function of IKKalpha in the control of epidermal differentiation, homoeostasis and tumorigenesis.
###end p 4
###begin title 5
###xml 37 40 37 40 <italic>Ikk</italic>
###xml 56 60 <span type="species:ncbi:10090">mice</span>
Defective epidermal morphogenesis in Ikkalpha-deficient mice
###end title 5
###begin p 6
###xml 97 102 90 95 <italic>et al</italic>
###xml 88 108 81 101 <xref ref-type="bibr" rid="b9">DiDonato <italic>et al</italic>, 1997</xref>
###xml 119 124 112 117 <italic>et al</italic>
###xml 110 130 103 123 <xref ref-type="bibr" rid="b47">Mercurio <italic>et al</italic>, 1997</xref>
###xml 141 146 134 139 <italic>et al</italic>
###xml 132 152 125 145 <xref ref-type="bibr" rid="b81">Woronicz <italic>et al</italic>, 1997</xref>
###xml 160 165 153 158 <italic>et al</italic>
###xml 154 171 147 164 <xref ref-type="bibr" rid="b86">Zandi <italic>et al</italic>, 1997</xref>
###xml 288 293 269 274 <italic>et al</italic>
###xml 279 299 260 280 <xref ref-type="bibr" rid="b60">Rothwarf <italic>et al</italic>, 1998</xref>
###xml 309 314 290 295 <italic>et al</italic>
###xml 301 320 282 301 <xref ref-type="bibr" rid="b82">Yamaoka <italic>et al</italic>, 1998</xref>
###xml 450 455 427 432 <italic>et al</italic>
###xml 441 461 418 438 <xref ref-type="bibr" rid="b60">Rothwarf <italic>et al</italic>, 1998</xref>
###xml 653 658 616 621 <italic>et al</italic>
###xml 646 664 609 627 <xref ref-type="bibr" rid="b72">Tanaka <italic>et al</italic>, 1999</xref>
###xml 669 674 632 637 <italic>et al</italic>
###xml 666 681 629 644 <xref ref-type="bibr" rid="b40">Li <italic>et al</italic>, 1999b</xref>
###xml 683 688 646 651 <xref ref-type="bibr" rid="b41">1999c</xref>
###xml 772 775 731 734 <italic>Ikk</italic>
###xml 907 912 862 867 <italic>et al</italic>
###xml 904 918 859 873 <xref ref-type="bibr" rid="b28">Hu <italic>et al</italic>, 1999</xref>
###xml 923 928 878 883 <italic>et al</italic>
###xml 920 935 875 890 <xref ref-type="bibr" rid="b39">Li <italic>et al</italic>, 1999a</xref>
###xml 944 949 899 904 <italic>et al</italic>
###xml 937 955 892 910 <xref ref-type="bibr" rid="b71">Takeda <italic>et al</italic>, 1999</xref>
###xml 966 969 921 924 <italic>Ikk</italic>
###xml 974 977 925 928 <sup>&#8211;/&#8211;</sup>
###xml 1141 1149 1092 1100 <xref ref-type="fig" rid="f1">Figure 1</xref>
###xml 1155 1160 1106 1111 <italic>et al</italic>
###xml 1152 1166 1103 1117 <xref ref-type="bibr" rid="b28">Hu <italic>et al</italic>, 1999</xref>
###xml 1175 1180 1126 1131 <italic>et al</italic>
###xml 1168 1186 1119 1137 <xref ref-type="bibr" rid="b71">Takeda <italic>et al</italic>, 1999</xref>
###xml 1196 1201 1147 1152 <italic>et al</italic>
###xml 1188 1207 1139 1158 <xref ref-type="bibr" rid="b85">Yoshida <italic>et al</italic>, 2000</xref>
###xml 790 794 <span type="species:ncbi:10090">mice</span>
###xml 978 982 <span type="species:ncbi:10090">mice</span>
###xml 1216 1220 <span type="species:ncbi:10090">mice</span>
The oligomeric IKK complex is composed of two catalytic subunits, IKKalpha and IKKbeta (DiDonato et al, 1997; Mercurio et al, 1997; Woronicz et al, 1997; Zandi et al, 1997), and a regulatory subunit named IKKgamma or NEMO (nuclear factor kappaB (NF-kappaB) essential modulator) (Rothwarf et al, 1998; Yamaoka et al, 1998). This complex is the key mediator of NF-kappaB activation in response to proinflammatory and innate immune challenges (Rothwarf et al, 1998). Although IKKalpha and IKKbeta share considerable sequence identity, it is IKKbeta that usually serves the more critical function in the activation of classical NF-kappaB signalling (Tanaka et al, 1999; Li et al, 1999b, 1999c). To determine the unique functions of IKKalpha, several groups have disrupted the Ikkalpha locus in mice and were surprised to find that it has an essential function in epidermal differentiation and morphogenesis (Hu et al, 1999; Li et al, 1999a; Takeda et al, 1999). Newborn Ikkalpha-/- mice present with multiple morphological defects, including shiny and translucent skin, absence of erupted whiskers, shortened limbs and truncated snout and tail (Figure 1) (Hu et al, 1999; Takeda et al, 1999; Yoshida et al, 2000). These mice develop to term but die shortly after birth, probably as a consequence of a major skin barrier defect that results in severe dehydration.
###end p 6
###begin p 7
###xml 4 7 4 7 <italic>Ikk</italic>
###xml 12 15 8 11 <sup>&#8211;/&#8211;</sup>
###xml 192 201 188 197 <xref ref-type="fig" rid="f2">Figure 2A</xref>
###xml 207 212 203 208 <italic>et al</italic>
###xml 204 218 200 214 <xref ref-type="bibr" rid="b28">Hu <italic>et al</italic>, 1999</xref>
###xml 227 232 223 228 <italic>et al</italic>
###xml 220 238 216 234 <xref ref-type="bibr" rid="b71">Takeda <italic>et al</italic>, 1999</xref>
###xml 471 476 467 472 <italic>et al</italic>
###xml 468 482 464 478 <xref ref-type="bibr" rid="b28">Hu <italic>et al</italic>, 1999</xref>
###xml 491 496 487 492 <italic>et al</italic>
###xml 484 502 480 498 <xref ref-type="bibr" rid="b71">Takeda <italic>et al</italic>, 1999</xref>
###xml 597 600 593 596 <italic>Ikk</italic>
###xml 605 608 597 600 <sup>&#8211;/&#8211;</sup>
###xml 623 628 615 620 <italic>et al</italic>
###xml 620 634 612 626 <xref ref-type="bibr" rid="b28">Hu <italic>et al</italic>, 1999</xref>
###xml 643 648 635 640 <italic>et al</italic>
###xml 636 654 628 646 <xref ref-type="bibr" rid="b71">Takeda <italic>et al</italic>, 1999</xref>
###xml 752 757 744 749 <italic>et al</italic>
###xml 745 763 737 755 <xref ref-type="bibr" rid="b71">Takeda <italic>et al</italic>, 1999</xref>
###xml 950 955 942 947 <italic>et al</italic>
###xml 947 961 939 953 <xref ref-type="bibr" rid="b28">Hu <italic>et al</italic>, 1999</xref>
###xml 970 975 962 967 <italic>et al</italic>
###xml 963 981 955 973 <xref ref-type="bibr" rid="b71">Takeda <italic>et al</italic>, 1999</xref>
###xml 984 993 976 985 <xref ref-type="fig" rid="f2">Figure 2B</xref>
###xml 1067 1070 1059 1062 <italic>Ikk</italic>
###xml 1075 1078 1063 1066 <sup>&#8211;/&#8211;</sup>
###xml 1183 1204 1171 1192 <xref ref-type="bibr" rid="b34">Koster and Roop, 2007</xref>
###xml 1439 1447 1423 1431 <xref ref-type="fig" rid="f3">Figure 3</xref>
###xml 739 743 <span type="species:ncbi:10090">mice</span>
The Ikkalpha-/- epidermis is characterized by the presence of basal and suprabasal layers, both in a highly proliferative state, and complete absence of the granular and the cornified layers (Figure 2A) (Hu et al, 1999; Takeda et al, 1999). At the molecular level, these anomalies are characterized by the expression of CK5 and CK14 as well as proliferating cell markers, such as CK6, PCNA (proliferating cell nuclear antigen) and Ki67 in basal and suprabasal layers (Hu et al, 1999; Takeda et al, 1999). In contrast, CK1 and CK10 are appropriately expressed in the first suprabasal layers of the Ikkalpha-/- epidermis (Hu et al, 1999; Takeda et al, 1999). Involucrin is also synthesized in the upper part of the suprabasal layer of these mice (Takeda et al, 1999), indicating that an early step in the differentiation process still takes place, although late terminal differentiation markers, including loricrin and filaggrin, are not expressed (Hu et al, 1999; Takeda et al, 1999) (Figure 2B). It was suggested that the highly proliferative suprabasal cells of the Ikkalpha-/- epidermis, which express CK1 and CK10, are reminiscent of intermediate cells rather than spinous cells (Koster and Roop, 2007). Hence, the most critical function of IKKalpha may be induction of cell cycle exit needed for converting basal and intermediate keratinocytes to spinous cells. When this step fails, all subsequent differentiation states are aborted (Figure 3).
###end p 7
###begin title 8
Nuclear IKKalpha controls terminal differentiation of keratinocytes
###end title 8
###begin p 9
###xml 172 177 164 169 <italic>et al</italic>
###xml 169 183 161 175 <xref ref-type="bibr" rid="b29">Hu <italic>et al</italic>, 2001</xref>
###xml 186 189 178 181 <italic>Ikk</italic>
###xml 194 197 182 185 <sup>&#8211;/&#8211;</sup>
###xml 272 277 256 261 <italic>et al</italic>
###xml 269 283 253 267 <xref ref-type="bibr" rid="b28">Hu <italic>et al</italic>, 1999</xref>
###xml 292 297 276 281 <italic>et al</italic>
###xml 285 303 269 287 <xref ref-type="bibr" rid="b71">Takeda <italic>et al</italic>, 1999</xref>
###xml 319 327 303 307 <italic>Ikk&#945;</italic>
###xml 327 330 307 310 <sup>&#8211;/&#8211;</sup>
###xml 494 499 466 471 <italic>et al</italic>
###xml 491 505 463 477 <xref ref-type="bibr" rid="b29">Hu <italic>et al</italic>, 2001</xref>
###xml 754 769 714 729 <italic>stratum corneum</italic>
###xml 787 792 747 752 <italic>et al</italic>
###xml 781 798 741 758 <xref ref-type="bibr" rid="b65">Seitz <italic>et al</italic>, 1998</xref>
###xml 809 814 769 774 <italic>et al</italic>
###xml 800 820 760 780 <xref ref-type="bibr" rid="b20">Gugasyan <italic>et al</italic>, 2004</xref>
###xml 828 833 788 793 <italic>et al</italic>
###xml 822 839 782 799 <xref ref-type="bibr" rid="b87">Zhang <italic>et al</italic>, 2004</xref>
###xml 530 545 <span type="species:ncbi:10090">transgenic mice</span>
###xml 640 644 <span type="species:ncbi:10090">mice</span>
Control of epidermal proliferation and differentiation by IKKalpha does not involve its protein kinase function and is completely independent from NF-kappaB activation (Hu et al, 2001). Ikkalpha-/- keratinocytes do not exhibit a primary defect in NF-kappaB activation (Hu et al, 1999; Takeda et al, 1999). In contrast, Ikkalpha-/- keratinocytes display higher IKK and NF-kappaB activities than wild-type (WT) cells after incubation with either tumour necrosis factor-alpha or interleukin-1 (Hu et al, 2001). The observations that transgenic mice overexpressing a dominant inhibitor of NF-kappaB function (IkappaBalphaM) in the epidermis or mice lacking both RelA and c-Rel display epidermal hyperplasia that does not disrupt terminal differentiation and stratum corneum formation (Seitz et al, 1998; Gugasyan et al, 2004; Zhang et al, 2004), are consistent with the NF-kappaB-independent action of IKKalpha in the epidermis.
###end p 9
###begin p 10
###xml 12 19 12 19 <italic>in vivo</italic>
###xml 30 33 30 33 <italic>Ikk</italic>
###xml 38 41 34 37 <sup>&#8211;/&#8211;</sup>
###xml 163 165 159 161 <sup>2+</sup>
###xml 170 175 166 171 <italic>et al</italic>
###xml 167 181 163 177 <xref ref-type="bibr" rid="b28">Hu <italic>et al</italic>, 1999</xref>
###xml 183 187 179 183 <xref ref-type="bibr" rid="b29">2001</xref>
###xml 190 193 186 189 <italic>Ikk</italic>
###xml 198 201 190 193 <sup>&#8211;/&#8211;</sup>
###xml 243 251 235 243 <italic>in vitro</italic>
###xml 418 423 406 411 <italic>et al</italic>
###xml 415 429 403 417 <xref ref-type="bibr" rid="b29">Hu <italic>et al</italic>, 2001</xref>
###xml 552 557 536 541 <italic>et al</italic>
###xml 548 563 532 547 <xref ref-type="bibr" rid="b68">Sil <italic>et al</italic>, 2004</xref>
###xml 748 753 728 733 <italic>et al</italic>
###xml 744 759 724 739 <xref ref-type="bibr" rid="b68">Sil <italic>et al</italic>, 2004</xref>
###xml 965 970 934 939 <italic>et al</italic>
###xml 954 976 923 945 <xref ref-type="bibr" rid="b8">Descargues <italic>et al</italic>, 2008</xref>
###xml 1009 1014 978 983 <italic>et al</italic>
###xml 1003 1020 972 989 <xref ref-type="bibr" rid="b44">Maeda <italic>et al</italic>, 2007</xref>
As observed in vivo, isolated Ikkalpha-/- keratinocytes are hyperproliferative and do not respond to differentiation-inducing signals such as confluence or high Ca2+ (Hu et al, 1999, 2001). Ikkalpha-/- keratinocytes, however, do differentiate in vitro when transduced by an adenovirus expressing a 'kinase-dead' form of IKKalpha, indicating that the kinase function is dispensable for keratinocyte differentiation (Hu et al, 2001). Instead, IKKalpha needs to enter the nucleus to induce keratinocyte cell cycle arrest and terminal differentiation (Sil et al, 2004). Nuclear entry depends on a nuclear localization sequence (NLS) within the IKKalpha kinase domain, the disruption of which prevents the induction of keratinocyte differentiation (Sil et al, 2004). An NLS is absent from IKKbeta, which cannot substitute for IKKalpha in keratinocyte differentiation and growth arrest. IKKalpha is also nuclear in basal and suprabasal cells of the epidermis (Descargues et al, 2008) and the oral epithelium (Maeda et al, 2007), findings that are consistent with the cell culture results.
###end p 10
###begin p 11
###xml 277 280 273 276 <italic>Ikk</italic>
###xml 285 288 277 280 <sup>&#8211;/&#8211;</sup>
###xml 299 304 291 296 <italic>et al</italic>
###xml 296 310 288 302 <xref ref-type="bibr" rid="b29">Hu <italic>et al</italic>, 2001</xref>
###xml 371 374 363 366 <italic>Ikk</italic>
###xml 379 382 367 370 <sup>&#8211;/&#8211;</sup>
###xml 439 442 427 430 <italic>Ikk</italic>
###xml 603 608 583 588 <italic>et al</italic>
###xml 600 614 580 594 <xref ref-type="bibr" rid="b29">Hu <italic>et al</italic>, 2001</xref>
###xml 834 848 814 828 <xref ref-type="bibr" rid="b80">Wessells, 1977</xref>
###xml 906 909 886 889 <italic>Ikk</italic>
###xml 1034 1037 1010 1013 <italic>Ikk</italic>
###xml 1060 1065 1032 1037 <italic>et al</italic>
###xml 1053 1071 1025 1043 <xref ref-type="bibr" rid="b17">Gareus <italic>et al</italic>, 2007</xref>
###xml 1218 1221 1186 1189 <italic>Ikk</italic>
###xml 1322 1330 1286 1294 <italic>in vitro</italic>
###xml 1339 1344 1303 1308 <italic>et al</italic>
###xml 1332 1350 1296 1314 <xref ref-type="bibr" rid="b17">Gareus <italic>et al</italic>, 2007</xref>
###xml 1389 1392 1353 1356 <italic>Ikk</italic>
###xml 1416 1421 1376 1381 <italic>et al</italic>
###xml 1413 1427 1373 1387 <xref ref-type="bibr" rid="b29">Hu <italic>et al</italic>, 2001</xref>
###xml 1740 1745 1692 1697 <italic>et al</italic>
###xml 1736 1751 1688 1703 <xref ref-type="bibr" rid="b68">Sil <italic>et al</italic>, 2004</xref>
###xml 423 427 <span type="species:ncbi:10090">mice</span>
###xml 1288 1293 <span type="species:ncbi:10090">mouse</span>
###xml 1407 1411 <span type="species:ncbi:10090">mice</span>
The function of IKKalpha in the keratinocyte nucleus is linked to the production of a yet-to-be identified soluble factor or group of factors termed keratinocyte differentiation-inducing factor (kDIF) that can induce the expression of terminal differentiation markers, even in Ikkalpha-/- cells (Hu et al, 2001). Consistent with the existence of kDIF, transplantation of Ikkalpha-/- skin onto the back of immuodeficient WT mice allows the Ikkalpha-deficient epidermis to undergo normal differentiation, suggesting that the requirement for IKKalpha can be bypassed by factors produced by normal skin (Hu et al, 2001). These experiments do not exclude the possibility that another important source of kDIF or similarly acting factors are dermal fibroblasts, which are well known to produce factors that control epidermal morphogenesis (Wessells, 1977). In support of this hypothesis, a keratinocyte-specific Ikkalpha disruption results in a less severe epidermal differentiation defect with altered skin barrier function than the total Ikkalpha knockout (Gareus et al, 2007). These results were interpreted to suggest that Ikkalpha functions non-autonomously in the dermis to control epidermal differentiation. However, Ikkalpha-deficient keratinocytes from the epidermal-specific knockout mouse still fail to differentiate in vitro (Gareus et al, 2007), similar to keratinocytes from total Ikkalpha knockout mice (Hu et al, 2001). Collectively, these results indicate that IKKalpha functions within epidermal keratinocytes and probably in dermal fibroblasts to induce keratinocyte differentiation. As keratinocyte-restricted expression of IKKalpha, unlike the keratinocyte-specific knockout, does not result in a differentiation defect (Sil et al, 2004), it appears that the keratinocyte is the major site of IKKalpha action with respect to keratinocyte differentiation and epidermal-directed morphogenetic events.
###end p 11
###begin title 12
IKKalpha is a critical component of a Smad4-independent TGFbeta-Smad2/3 signalling pathway
###end title 12
###begin p 13
###xml 55 58 51 54 <italic>Ikk</italic>
###xml 63 66 55 58 <sup>&#8211;/&#8211;</sup>
###xml 168 173 160 165 <italic>et al</italic>
###xml 165 179 157 171 <xref ref-type="bibr" rid="b29">Hu <italic>et al</italic>, 2001</xref>
###xml 452 455 436 439 <italic>Ikk</italic>
###xml 460 463 440 443 <sup>&#8211;/&#8211;</sup>
###xml 503 507 483 487 <italic>Mad1</italic>
###xml 512 517 492 497 <italic>Ovol1</italic>
###xml 530 535 510 515 <italic>et al</italic>
###xml 519 541 499 521 <xref ref-type="bibr" rid="b8">Descargues <italic>et al</italic>, 2008</xref>
###xml 589 590 569 570 <italic>c</italic>
###xml 591 594 571 574 <italic>Myc</italic>
###xml 756 761 736 741 <italic>et al</italic>
###xml 751 767 731 747 <xref ref-type="bibr" rid="b76">Watt <italic>et al</italic>, 2008</xref>
###xml 973 978 953 958 <italic>et al</italic>
###xml 968 984 948 964 <xref ref-type="bibr" rid="b1">Ayer <italic>et al</italic>, 1993</xref>
###xml 995 1000 975 980 <italic>et al</italic>
###xml 986 1006 966 986 <xref ref-type="bibr" rid="b19">Grandori <italic>et al</italic>, 2000</xref>
###xml 1009 1013 989 993 <italic>Mad1</italic>
###xml 1013 1016 993 996 <sup>&#8211;/&#8211;</sup>
###xml 1073 1078 1053 1058 <italic>et al</italic>
###xml 1067 1084 1047 1064 <xref ref-type="bibr" rid="b14">Foley <italic>et al</italic>, 1998</xref>
###xml 1095 1100 1075 1080 <italic>et al</italic>
###xml 1086 1106 1066 1086 <xref ref-type="bibr" rid="b19">Grandori <italic>et al</italic>, 2000</xref>
###xml 1165 1168 1145 1148 <italic>Mad</italic>
###xml 1186 1190 1166 1170 <italic>Mad2</italic>
###xml 1192 1196 1172 1176 <italic>Mad3</italic>
###xml 1201 1205 1181 1185 <italic>Mad4</italic>
###xml 1239 1243 1219 1223 <italic>Mad1</italic>
###xml 1280 1284 1260 1264 <italic>Mad2</italic>
###xml 1289 1293 1269 1273 <italic>Mad3</italic>
###xml 1527 1532 1503 1508 <italic>et al</italic>
###xml 1523 1538 1499 1514 <xref ref-type="bibr" rid="b5">Dai <italic>et al</italic>, 1998</xref>
###xml 1551 1556 1527 1532 <italic>et al</italic>
###xml 1540 1562 1516 1538 <xref ref-type="bibr" rid="b8">Descargues <italic>et al</italic>, 2008</xref>
###xml 1565 1570 1541 1546 <italic>Ovol1</italic>
###xml 1570 1573 1546 1549 <sup>&#8211;/&#8211;</sup>
###xml 1664 1669 1640 1645 <italic>et al</italic>
###xml 1660 1675 1636 1651 <xref ref-type="bibr" rid="b5">Dai <italic>et al</italic>, 1998</xref>
###xml 1715 1720 1691 1696 <italic>Ovol1</italic>
###xml 1720 1723 1696 1699 <sup>&#8211;/&#8211;</sup>
###xml 1766 1774 1742 1750 <italic>in vitro</italic>
###xml 1776 1781 1752 1757 <italic>Ovol1</italic>
###xml 1781 1784 1757 1760 <sup>&#8211;/&#8211;</sup>
###xml 1884 1886 1860 1862 <sup>2+</sup>
###xml 1904 1909 1877 1882 <italic>et al</italic>
###xml 1899 1915 1872 1888 <xref ref-type="bibr" rid="b50">Nair <italic>et al</italic>, 2006</xref>
###xml 1983 1988 1956 1961 <italic>c-Myc</italic>
###xml 2047 2052 2020 2025 <italic>et al</italic>
###xml 2042 2058 2015 2031 <xref ref-type="bibr" rid="b50">Nair <italic>et al</italic>, 2006</xref>
###xml 2241 2249 2210 2218 <xref ref-type="fig" rid="f4">Figure 4</xref>
###xml 2395 2400 2361 2366 <italic>c-Myc</italic>
###xml 2435 2440 2401 2406 <italic>et al</italic>
###xml 2430 2446 2396 2412 <xref ref-type="bibr" rid="b4">Chen <italic>et al</italic>, 2002</xref>
###xml 2449 2457 2415 2423 <xref ref-type="fig" rid="f4">Figure 4</xref>
###xml 1017 1021 <span type="species:ncbi:10090">mice</span>
###xml 1580 1584 <span type="species:ncbi:10090">mice</span>
The most immediate effect of IKKalpha re-expression in Ikkalpha-/- keratinocytes is cell cycle withdrawal, which precedes the expression of differentiation markers (Hu et al, 2001). Thus, to understand the molecular function of IKKalpha, we searched for cell cycle-related target genes, the expression of which is IKKalpha dependent. This search netted several genes encoding negative cell cycle regulators, the expression of which is downregulated in Ikkalpha-/- keratinocytes and epidermis, including Mad1 and Ovol1 (Descargues et al, 2008), which encode negative regulators of Myc. The c-Myc oncogene is thought to influence the balance between keratinocyte proliferation and differentiation, depending on the intensity and timing of its activity (Watt et al, 2008). Mad1 is a basic region/helix-loop-helix/leucine zipper transcriptional regulator that dimerizes with Max to form Mad:Max heterodimers that antagonize the transcriptional function of Myc:Max dimers (Ayer et al, 1993; Grandori et al, 2000). Mad1-/- mice, however, are viable, phenotypically normal (Foley et al, 1998; Grandori et al, 2000) and do not show any epidermal defect. Most likely, other Mad genes, including Mad2, Mad3 and Mad4, are functionally redundant with Mad1 and compensate for its loss. Indeed Mad2 and Mad3 are also induced in keratinocytes in an IKKalpha-dependent manner (unpublished data). Ovol1 is a zinc-finger-containing transcription factor, which, similar to Mad1, is also expressed in differentiating suprabasal keratinocytes (Dai et al, 1998; Descargues et al, 2008). Ovol1-/- adult mice present with aberrant hair formation but normal epidermal differentiation (Dai et al, 1998). However, the suprabasal epidermis of Ovol1-/- embryos shows increased proliferation and in vitro, Ovol1-/- keratinocytes fail to exit the cell cycle in response to growth-inhibitory signals, such as high Ca2+ or TGFbeta (Nair et al, 2006). This defect may be explained in part by abnormal upregulation of c-Myc, which is a direct target of Ovol1 in keratinocytes (Nair et al, 2006). Thus, IKKalpha controls keratinocyte proliferation and cycling through the regulation of several Myc antagonists to allow keratinocytes to embark on their differentiation pathway (Figure 4). Interestingly, another TGFbeta-related mechanism involving Smad3/4 and E2F4/5 transcription factors has been shown earlier to directly inhibit c-Myc expression in keratinocytes (Chen et al, 2002) (Figure 4). Although this signalling pathway triggers antiproliferative effects of TGFbeta in keratinocytes, its impact on keratinocyte differentiation is unknown.
###end p 13
###begin p 14
###xml 119 124 116 121 <italic>et al</italic>
###xml 111 130 108 127 <xref ref-type="bibr" rid="b74">Vastrik <italic>et al</italic>, 1995</xref>
###xml 138 143 135 140 <italic>et al</italic>
###xml 132 149 129 146 <xref ref-type="bibr" rid="b18">Gomis <italic>et al</italic>, 2006</xref>
###xml 528 550 512 534 <xref ref-type="bibr" rid="b66">Shi and Massague, 2003</xref>
###xml 552 574 536 558 <xref ref-type="bibr" rid="b13">Feng and Derynck, 2005</xref>
###xml 576 600 560 584 <xref ref-type="bibr" rid="b63">Schmierer and Hill, 2007</xref>
###xml 1152 1174 1136 1158 <xref ref-type="bibr" rid="b66">Shi and Massague, 2003</xref>
###xml 1176 1198 1160 1182 <xref ref-type="bibr" rid="b13">Feng and Derynck, 2005</xref>
###xml 1200 1224 1184 1208 <xref ref-type="bibr" rid="b63">Schmierer and Hill, 2007</xref>
Mad1 and Ovol1 are involved in the inhibition of keratinocyte proliferation induced by TGFbeta family members (Vastrik et al, 1995; Gomis et al, 2006), suggesting a link between IKKalpha and the TGFbeta signalling pathway. TGFbeta family members, including TGFbetas, activins and BMPs, are cytokines that control cell growth, differentiation and deposition of extracellular matrix through binding to heterodimeric cell surface receptor complexes composed of type I and II subunits, and intracellular Smad transcription factors (Shi and Massague, 2003; Feng and Derynck, 2005; Schmierer and Hill, 2007). The eight mammalian Smad proteins are divided into three distinct groups: receptor-activated Smads (R-Smads: Smad1, Smad2, Smad3, Smad5 and Smad8), a unique common Smad mediator (Co-Smads: Smad4) and inhibitory Smads (i-Smads: Smad6 and Smad7). On ligand binding, the type II receptor activates the type I receptor through its kinase domain, and the type I receptor in turn phosphorylates R-Smads. The activated R-Smads form heterodimeric complexes with Smad4, which accumulate in the nucleus and directly repress or activate specific target genes (Shi and Massague, 2003; Feng and Derynck, 2005; Schmierer and Hill, 2007).
###end p 14
###begin p 15
###xml 177 182 174 179 <italic>et al</italic>
###xml 174 188 171 185 <xref ref-type="bibr" rid="b24">He <italic>et al</italic>, 2001</xref>
###xml 193 198 190 195 <italic>et al</italic>
###xml 190 204 187 201 <xref ref-type="bibr" rid="b35">Li <italic>et al</italic>, 2003</xref>
###xml 394 399 391 396 <italic>et al</italic>
###xml 383 405 380 402 <xref ref-type="bibr" rid="b8">Descargues <italic>et al</italic>, 2008</xref>
###xml 593 598 587 592 <italic>et al</italic>
###xml 590 604 584 598 <xref ref-type="bibr" rid="b35">Li <italic>et al</italic>, 2003</xref>
###xml 728 733 718 723 <italic>et al</italic>
###xml 717 739 707 729 <xref ref-type="bibr" rid="b8">Descargues <italic>et al</italic>, 2008</xref>
###xml 907 912 893 898 <italic>trans</italic>
###xml 980 994 966 980 <xref ref-type="bibr" rid="b45">Massague, 2000</xref>
###xml 996 1018 982 1004 <xref ref-type="bibr" rid="b13">Feng and Derynck, 2005</xref>
###xml 1185 1189 1164 1168 <italic>Mad1</italic>
###xml 1202 1207 1181 1186 <italic>et al</italic>
###xml 1191 1213 1170 1192 <xref ref-type="bibr" rid="b8">Descargues <italic>et al</italic>, 2008</xref>
###xml 1247 1252 1226 1231 <italic>Ovol1</italic>
###xml 1276 1279 1255 1258 <italic>Ikk</italic>
###xml 1284 1287 1259 1262 <sup>&#8211;/&#8211;</sup>
###xml 1364 1368 1336 1340 <italic>Mad1</italic>
###xml 1524 1527 1496 1499 <italic>Ikk</italic>
###xml 1532 1535 1500 1503 <sup>&#8211;/&#8211;</sup>
###xml 1558 1563 1526 1531 <italic>et al</italic>
###xml 1547 1569 1515 1537 <xref ref-type="bibr" rid="b8">Descargues <italic>et al</italic>, 2008</xref>
###xml 1860 1865 1817 1822 <italic>et al</italic>
###xml 1854 1871 1811 1828 <xref ref-type="bibr" rid="b54">Owens <italic>et al</italic>, 2008</xref>
###xml 1906 1910 1863 1867 <italic>Mad1</italic>
###xml 1947 1952 1904 1909 <italic>et al</italic>
###xml 1940 1958 1897 1915 <xref ref-type="bibr" rid="b79">Werner <italic>et al</italic>, 2001</xref>
###xml 2072 2076 2025 2029 <italic>Mad1</italic>
###xml 2136 2139 2089 2092 <italic>Id1</italic>
###xml 2141 2144 2094 2097 <italic>Id2</italic>
###xml 2149 2152 2102 2105 <italic>Id3</italic>
###xml 2184 2189 2137 2142 <italic>et al</italic>
###xml 2177 2195 2130 2148 <xref ref-type="bibr" rid="b61">Rotzer <italic>et al</italic>, 2006</xref>
###xml 2419 2422 2364 2367 <italic>Ikk</italic>
###xml 2427 2430 2368 2371 <sup>&#8211;/&#8211;</sup>
###xml 2462 2466 2403 2407 <italic>Mad1</italic>
###xml 2479 2487 2420 2428 <xref ref-type="fig" rid="f5">Figure 5</xref>
###xml 478 482 <span type="species:ncbi:10090">mice</span>
TGFbeta family members, their receptors and Smad transcription factors are abundantly expressed in epidermal keratinocytes, suggesting homoeostatic and regulatory functions (He et al, 2001; Li et al, 2003). Phosphorylated Smad2 and Smad3 proteins are concentrated in the nuclei of basal and suprabasal keratinocytes, whereas nuclear Smad4 staining is more preeminent in basal cells (Descargues et al, 2008). Nonetheless, alterations of TGFbeta signalling in transgenic/knockout mice have often resulted only in minor epidermal defects, thereby obscuring its exact functions in this tissue (Li et al, 2003). We recently found that IKKalpha interacts strongly with Smad3 and weakly with Smad2, but does not bind Smad4 (Descargues et al, 2008). IKKalpha associates with the C-terminal MH2 domain of Smad3 through its kinase domain (unpublished observations). The R-Smad MH2 domain is known to be essential for trans-activation, phosphorylation by type I receptors and Smad4 binding (Massague, 2000; Feng and Derynck, 2005). On stimulation by TGFbeta1, IKKalpha and Smad3 form a transcriptional complex that accumulates in the keratinocyte nucleus to directly control the transcription of Mad1 (Descargues et al, 2008). Similar findings were made for Ovol1 (unpublished data). In Ikkalpha-/- keratinocytes stimulated with TGFbeta1, Smad3 is no longer recruited to the Mad1 regulatory region despite its normal association with Smad4. Furthermore, nuclear staining for activated Smad2 and Smad3 is dramatically diminished in the Ikkalpha-/- epidermis (Descargues et al, 2008). Taken together, these results indicate that IKKalpha is required for nuclear accumulation and chromatin recruitment of phosphorylated Smad2 and Smad3 to IKKalpha-regulated genes in response to TGFbeta1. Interestingly, activin A, an important regulator of epidermal differentiation (Owens et al, 2008), is involved in the induction of Mad1 expression in keratinocytes (Werner et al, 2001). As a result, one may speculate that the IKKalpha-Smad2/3 complex forms and activates anti-Myc genes, including Mad1, on activin A signals. As activin A also downregulates the Id1, Id2 and Id3 genes in keratinocytes (Rotzer et al, 2006), it could also be interesting to analyse whether this signalling pathway depends on IKKalpha. Finally, we found that kDIF functions downstream of the IKKalpha-Smad2/3 signalling pathway as it can induce differentiation of Ikkalpha-/- keratinocytes without inducing Mad1 expression (Figure 5). Exactly how kDIF functions and what it is composed of remain to be determined.
###end p 15
###begin p 16
###xml 224 229 224 229 <italic>et al</italic>
###xml 220 235 220 235 <xref ref-type="bibr" rid="b89">Zhu <italic>et al</italic>, 1998</xref>
###xml 243 248 243 248 <italic>et al</italic>
###xml 237 254 237 254 <xref ref-type="bibr" rid="b6">Datto <italic>et al</italic>, 1999</xref>
###xml 261 266 261 266 <italic>et al</italic>
###xml 256 272 256 272 <xref ref-type="bibr" rid="b84">Yang <italic>et al</italic>, 1999</xref>
###xml 332 351 332 351 <xref ref-type="bibr" rid="b51">Nomura and Li, 1998</xref>
###xml 361 366 361 366 <italic>et al</italic>
###xml 353 372 353 372 <xref ref-type="bibr" rid="b75">Waldrip <italic>et al</italic>, 1998</xref>
###xml 384 389 384 389 <italic>et al</italic>
###xml 374 395 374 395 <xref ref-type="bibr" rid="b77">Weinstein <italic>et al</italic>, 1998</xref>
###xml 403 408 403 408 <italic>et al</italic>
###xml 397 414 397 414 <xref ref-type="bibr" rid="b27">Heyer <italic>et al</italic>, 1999</xref>
###xml 502 507 502 507 <italic>Smad3</italic>
###xml 524 529 524 529 <italic>Smad2</italic>
###xml 568 573 568 573 <italic>et al</italic>
###xml 557 579 557 579 <xref ref-type="bibr" rid="b8">Descargues <italic>et al</italic>, 2008</xref>
###xml 748 750 748 750 <sup>2+</sup>
###xml 763 768 763 768 <italic>et al</italic>
###xml 752 774 752 774 <xref ref-type="bibr" rid="b8">Descargues <italic>et al</italic>, 2008</xref>
###xml 1130 1145 1123 1138 <italic>stratum corneum</italic>
###xml 1168 1173 1161 1166 <italic>et al</italic>
###xml 1157 1179 1150 1172 <xref ref-type="bibr" rid="b8">Descargues <italic>et al</italic>, 2008</xref>
###xml 1352 1357 1341 1346 <italic>et al</italic>
###xml 1341 1363 1330 1352 <xref ref-type="bibr" rid="b8">Descargues <italic>et al</italic>, 2008</xref>
###xml 976 991 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1209 1213 <span type="species:ncbi:10090">mice</span>
The results mentioned above provided the first clear evidence for a critical function for Smad transcription factors in epidermal differentiation. Although Smad3 deficiency alone does not result in any cutaneous defect (Zhu et al, 1998; Datto et al, 1999; Yang et al, 1999) and the loss of Smad2 leads to early embryonic lethality (Nomura and Li, 1998; Waldrip et al, 1998; Weinstein et al, 1998; Heyer et al, 1999), loricrin and filaggrin expression is barely detectable in E15.5 embryos lacking both Smad3 alleles and one Smad2 allele in their epidermis (Descargues et al, 2008). Similarly, siRNA-mediated Smad2 knockdown in Smad3-deficient keratinocytes inhibited the expression of loricrin and filaggrin, as well as Mad1, in response to high Ca2+ (Descargues et al, 2008). These results suggest that Smad2 and Smad3 are functionally redundant. The importance of the TGFbeta-Smad2/3-IKKalpha axis for proper epidermal differentiation is also underscored by the analysis of transgenic mice in which the i-Smad Smad7 is inducibly expressed in the epidermis, resulting in defective expression of loricrin and filaggrin and failed stratum corneum formation (Descargues et al, 2008). Consequently, these mutant mice display epidermal hyperplasia due to abnormal proliferation of suprabasal keratinocytes and loss of nuclear IKKalpha and Mad1 (Descargues et al, 2008).
###end p 16
###begin p 17
###xml 196 201 189 194 <italic>et al</italic>
###xml 185 207 178 200 <xref ref-type="bibr" rid="b8">Descargues <italic>et al</italic>, 2008</xref>
###xml 268 270 261 263 <sup>2+</sup>
###xml 383 388 376 381 <italic>Smad4</italic>
###xml 390 395 383 388 <italic>Smad4</italic>
###xml 395 406 388 391 <sup>&#916;/&#916;</sup>
###xml 594 609 579 594 <italic>stratum corneum</italic>
###xml 626 631 611 616 <italic>et al</italic>
###xml 621 637 606 622 <xref ref-type="bibr" rid="b83">Yang <italic>et al</italic>, 2005</xref>
###xml 644 649 629 634 <italic>et al</italic>
###xml 639 655 624 640 <xref ref-type="bibr" rid="b56">Qiao <italic>et al</italic>, 2006</xref>
###xml 759 764 740 745 <italic>Smad4</italic>
###xml 764 775 745 748 <sup>&#916;/&#916;</sup>
###xml 840 845 813 818 <italic>et al</italic>
###xml 829 851 802 824 <xref ref-type="bibr" rid="b8">Descargues <italic>et al</italic>, 2008</xref>
###xml 1191 1196 1150 1155 <italic>et al</italic>
###xml 1188 1202 1147 1161 <xref ref-type="bibr" rid="b25">He <italic>et al</italic>, 2006</xref>
###xml 1390 1395 1342 1347 <italic>et al</italic>
###xml 1383 1401 1335 1353 <xref ref-type="bibr" rid="b10">Dupont <italic>et al</italic>, 2005</xref>
###xml 342 346 <span type="species:ncbi:10090">mice</span>
###xml 407 411 <span type="species:ncbi:10090">mice</span>
###xml 420 424 <span type="species:ncbi:10090">mice</span>
Surprisingly, this new TGFbeta response pathway centred around Smad2/3-IKKalpha complex formation is independent of Smad4. Smad4-deficient keratinocytes display normal Mad1 expression (Descargues et al, 2008) and undergo terminal differentiation in response to high Ca2+ (unpublished data). These results are consistent with the phenotype of mice with epidermal-specific deletion of Smad4 (Smad4Delta/Delta mice). These mice present with degeneration of hair follicles and dermal cysts that progress to skin tumours in old animals, but do not show any perturbated epidermal differentiation and stratum corneum formation (Yang et al, 2005; Qiao et al, 2006). Furthermore, activated Smad2 and Smad3, as well as IKKalpha, are normally localized in the nuclei of Smad4Delta/Delta keratinocytes, which display normal Mad1 expression (Descargues et al, 2008). Taken together, these results strongly indicate that Smad4 is not required for epidermal differentiation. The Smad4 independence of the TGFbeta-Smad2/3-IKKalpha signalling pathway is reminiscent of another TGFbeta signalling operative during erythroid development in which TIF1gamma (also called TRIM33 or ectodermin) replaces Smad4 (He et al, 2006). However, TIF1gamma is a RING-type ubiquitin ligase that can target Smad4 to degradation and can therefore function as a negative regulator of Smad4-dependent TGFbeta signalling (Dupont et al, 2005). Hence the exact function of TIF1gamma in TGFbeta signalling is not fully understood, and it is not known whether it affects the IKKalpha-dependent pathway.
###end p 17
###begin title 18
IKKalpha and squamous cell carcinoma
###end title 18
###begin p 19
###xml 94 99 90 95 <italic>et al</italic>
###xml 90 105 86 101 <xref ref-type="bibr" rid="b42">Liu <italic>et al</italic>, 2006</xref>
###xml 113 118 109 114 <italic>et al</italic>
###xml 107 124 103 120 <xref ref-type="bibr" rid="b44">Maeda <italic>et al</italic>, 2007</xref>
###xml 450 455 446 451 <italic>et al</italic>
###xml 442 461 438 457 <xref ref-type="bibr" rid="b31">Johnson <italic>et al</italic>, 1992</xref>
###xml 562 585 558 581 <xref ref-type="bibr" rid="b62">Rudolph and Zelac, 2004</xref>
###xml 587 600 583 596 <xref ref-type="bibr" rid="b21">Hampton, 2005</xref>
###xml 821 836 817 832 <xref ref-type="bibr" rid="b69">Silverman, 2001</xref>
###xml 984 999 980 995 <xref ref-type="bibr" rid="b69">Silverman, 2001</xref>
###xml 549 556 <span type="species:ncbi:4097">tobacco</span>
###xml 786 793 <span type="species:ncbi:4097">tobacco</span>
IKKalpha was recently identified as a tumour suppressor in squamous cell carcinoma (SCC) (Liu et al, 2006; Maeda et al, 2007). SCC is a cancer derived from squamous epithelia of the skin (epidermis), head and neck tissues (mouth, throat, oral and nasal cavities, esophagus) as well as other sites. SCC is the second most common skin cancer in Caucasians with an estimated incidence of 100 000-150 000 new cases per year in the United States (Johnson et al, 1992). Sun exposure and immune suppression increase the risk of SCC development and so does tobacco use (Rudolph and Zelac, 2004; Hampton, 2005). SCC of the oral cavity is one of the most prevalent cancers of the head and neck region with a worldwide incidence of 300 000 new cases per year, the occurrence of which is linked to tobacco use and betel nut chewing (Silverman, 2001). SCCs of the oral cavity are more aggressive than those developing from the skin, and are associated with a 5-year survival rate of about 50-55% (Silverman, 2001).
###end p 19
###begin p 20
###xml 115 118 115 118 <italic>RAS</italic>
###xml 120 123 120 123 <italic>MYC</italic>
###xml 125 129 125 129 <italic>EGFR</italic>
###xml 134 143 134 143 <italic>Cyclin D1</italic>
###xml 199 202 199 202 <italic>p53</italic>
###xml 207 210 207 210 <italic>p16</italic>
###xml 212 227 212 227 <xref ref-type="bibr" rid="b22">Hardisson, 2003</xref>
###xml 449 452 449 452 <italic>IKK</italic>
###xml 593 596 589 592 <italic>IKK</italic>
###xml 618 623 610 615 <italic>et al</italic>
###xml 614 629 606 621 <xref ref-type="bibr" rid="b42">Liu <italic>et al</italic>, 2006</xref>
###xml 717 720 705 708 <italic>IKK</italic>
###xml 810 815 794 799 <italic>et al</italic>
###xml 804 821 788 805 <xref ref-type="bibr" rid="b44">Maeda <italic>et al</italic>, 2007</xref>
###xml 1072 1077 1052 1057 <italic>et al</italic>
###xml 1068 1083 1048 1063 <xref ref-type="bibr" rid="b42">Liu <italic>et al</italic>, 2006</xref>
###xml 1141 1144 1121 1124 <italic>Ikk</italic>
###xml 1149 1152 1125 1128 <sup>+/&#8211;</sup>
###xml 1213 1216 1189 1192 <italic>Ikk</italic>
###xml 1329 1334 1297 1302 <italic>et al</italic>
###xml 1325 1340 1293 1308 <xref ref-type="bibr" rid="b42">Liu <italic>et al</italic>, 2006</xref>
###xml 1347 1352 1315 1320 <italic>et al</italic>
###xml 1342 1358 1310 1326 <xref ref-type="bibr" rid="b55">Park <italic>et al</italic>, 2007</xref>
###xml 1721 1726 1677 1682 <italic>et al</italic>
###xml 1704 1732 1660 1688 <xref ref-type="bibr" rid="b49">Moreno-Maldonado <italic>et al</italic>, 2008</xref>
###xml 1806 1811 1762 1767 <italic>et al</italic>
###xml 1799 1817 1755 1773 <xref ref-type="bibr" rid="b59">Rinker <italic>et al</italic>, 2001</xref>
###xml 525 530 <span type="species:ncbi:9606">human</span>
###xml 1062 1066 <span type="species:ncbi:10090">mice</span>
###xml 1153 1157 <span type="species:ncbi:10090">mice</span>
Molecular changes in SCCs are characterized by a marked heterogeneity and include activation of oncogenes, such as RAS, MYC, EGFR and Cyclin D1, as well inactivation of tumour suppressors, including p53 and p16 (Hardisson, 2003). These genetic alterations are thought to influence malignant keratinocyte behaviour and tumour progression, but the precise molecular pathogenesis of SCC is poorly understood. Interestingly, mutations in exon 15 of the IKKalpha locus were described in a few high-grade and poorly differentiated human SCCs of the skin and were shown to be associated with reduced IKKalpha expression (Liu et al, 2006). However, it seems that downregulation of IKKalpha due to epigenetic silencing of the IKKalpha locus is a more common occurrence seen in close to 30% of invasive oral SCCs (Maeda et al, 2007). It was also reported that overexpression of IKKalpha in the suprabasal compartment, which results in increased epidermal differentiation and reduced keratinocyte proliferation, inhibits chemically induced SCC formation and progression in mice (Liu et al, 2006). These results, together with enhanced SCC incidence in Ikkalpha+/- mice subjected to two-stage skin carcinogenesis and loss of Ikkalpha heterozygosity in the tumours, provide evidence that IKKalpha is a tumour suppressor in the epidermis (Liu et al, 2006; Park et al, 2007). This function of IKKalpha is probably mediated through the control of keratinocyte proliferation. The loss of nuclear IKKalpha contributes to malignant conversion of keratinocytes into less differentiated and proliferative carcinoma cells. However, a recent study has suggested that increased IKKalpha may be found in acantholytic SCC (ASCC) (Moreno-Maldonado et al, 2008), an histologic variant of SCC showing positive staining for CKs (Rinker et al, 2001). Unfortunately, the authors of that study have not carefully analysed whether ASCCs present with loss of nuclear IKKalpha, which would make their results more consistent with other studies mentioned above.
###end p 20
###begin p 21
###xml 259 264 256 261 <italic>et al</italic>
###xml 255 270 252 267 <xref ref-type="bibr" rid="b53">Oft <italic>et al</italic>, 1996</xref>
###xml 272 276 269 273 <xref ref-type="bibr" rid="b52">1998</xref>
###xml 278 303 275 300 <xref ref-type="bibr" rid="b67">Siegel and Massague, 2003</xref>
###xml 308 313 305 310 <italic>et al</italic>
###xml 305 320 302 317 <xref ref-type="bibr" rid="b37">Li <italic>et al</italic>, 2005a</xref>
###xml 322 326 319 323 <xref ref-type="bibr" rid="b36">2006</xref>
###xml 414 439 408 433 <xref ref-type="bibr" rid="b67">Siegel and Massague, 2003</xref>
###xml 444 449 438 443 <italic>et al</italic>
###xml 441 456 435 450 <xref ref-type="bibr" rid="b37">Li <italic>et al</italic>, 2005a</xref>
###xml 458 462 452 456 <xref ref-type="bibr" rid="b36">2006</xref>
SCC and other carcinoma cells are known to overproduce TGFbeta1 to modify their microenvironment through local immunosupression, extracellular matrix remodelling and neoangiogenesis, and these changes are required for tumour progression and invasiveness (Oft et al, 1996, 1998; Siegel and Massague, 2003; Li et al, 2005a, 2006). At the same time, carcinoma cells become resistant to TGFbeta-induced growth arrest (Siegel and Massague, 2003; Li et al, 2005a, 2006). Altered IKKalpha function may contribute, at least in part, to acquired resistance to TGFbeta1-induced growth arrest.
###end p 21
###begin title 22
Conclusions and future directions
###end title 22
###begin p 23
###xml 128 133 120 125 <italic>et al</italic>
###xml 119 139 111 131 <xref ref-type="bibr" rid="b9">DiDonato <italic>et al</italic>, 1997</xref>
###xml 150 155 142 147 <italic>et al</italic>
###xml 141 161 133 153 <xref ref-type="bibr" rid="b47">Mercurio <italic>et al</italic>, 1997</xref>
###xml 171 176 163 168 <italic>et al</italic>
###xml 163 182 155 174 <xref ref-type="bibr" rid="b57">Regnier <italic>et al</italic>, 1997</xref>
###xml 190 195 182 187 <italic>et al</italic>
###xml 184 201 176 193 <xref ref-type="bibr" rid="b86">Zandi <italic>et al</italic>, 1997</xref>
###xml 690 695 670 675 <italic>et al</italic>
###xml 679 701 659 681 <xref ref-type="bibr" rid="b8">Descargues <italic>et al</italic>, 2008</xref>
###xml 704 712 684 692 <xref ref-type="fig" rid="f6">Figure 6</xref>
###xml 854 858 827 831 <italic>Mad1</italic>
###xml 863 868 836 841 <italic>Ovol1</italic>
###xml 939 942 909 912 <italic>p21</italic>
###xml 944 947 914 917 <italic>p15</italic>
###xml 952 955 922 925 <italic>p27</italic>
###xml 1024 1029 994 999 <italic>et al</italic>
###xml 1013 1035 983 1005 <xref ref-type="bibr" rid="b8">Descargues <italic>et al</italic>, 2008</xref>
###xml 1246 1251 1213 1218 <italic>et al</italic>
###xml 1237 1257 1204 1224 <xref ref-type="bibr" rid="b46">Massague <italic>et al</italic>, 2000</xref>
Although IKKalpha was first identified as a catalytic subunit of the IKK complex, which mediates NF-kappaB activation (DiDonato et al, 1997; Mercurio et al, 1997; Regnier et al, 1997; Zandi et al, 1997), it has quickly emerged as a multifunctional protein with several unexpected and surprising activities. In the epidermis, IKKalpha has turned out to be a critical regulator of keratinocyte proliferation, differentiation and oncogenic transformation, and this function is completely unrelated to its protein kinase activity or NF-kappaB signalling. Instead, IKKalpha functions as a cofactor for Smad2/3 in a Smad4-independent pathway that inhibits keratinocytes proliferation (Descargues et al, 2008) (Figure 6). In this capacity, IKKalpha is required for the induction of a specific subset of TGFbeta-responsive genes that include the Myc antagonists Mad1 and Ovol1, but is not needed for other well-known TGFbeta target genes, such as p21, p15 and p27, encoding inhibitors of cyclin-dependent kinases (CDKs) (Descargues et al, 2008). This is reminiscent of the two different classes of antiproliferative gene responses: Myc repression and inhibition of CDKs, respectively, that are induced during TGFbeta-mediated cell cycle arrest (Massague et al, 2000). It is attractive to speculate that the tumour suppressive function of IKKalpha is exerted through this pathway as well.
###end p 23
###begin p 24
###xml 256 259 245 248 <italic>Ikk</italic>
###xml 264 267 249 252 <sup>&#8211;/&#8211;</sup>
###xml 281 286 266 271 <italic>et al</italic>
###xml 274 292 259 277 <xref ref-type="bibr" rid="b26">Herron <italic>et al</italic>, 2005</xref>
###xml 297 302 282 287 <italic>et al</italic>
###xml 294 309 279 294 <xref ref-type="bibr" rid="b38">Li <italic>et al</italic>, 2005b</xref>
###xml 320 325 305 310 <italic>et al</italic>
###xml 311 331 296 316 <xref ref-type="bibr" rid="b30">Ingraham <italic>et al</italic>, 2006</xref>
###xml 344 349 329 334 <italic>et al</italic>
###xml 333 355 318 340 <xref ref-type="bibr" rid="b58">Richardson <italic>et al</italic>, 2006</xref>
###xml 522 535 503 516 <xref ref-type="bibr" rid="b48">Mhawech, 2005</xref>
###xml 584 590 561 567 <italic>14-3-3</italic>
###xml 677 682 650 655 <italic>et al</italic>
###xml 673 688 646 661 <xref ref-type="bibr" rid="b88">Zhu <italic>et al</italic>, 2007</xref>
###xml 730 741 703 710 <italic>14-3-3&#963;</italic>
###xml 762 765 731 734 <italic>Ikk</italic>
###xml 770 773 735 738 <sup>&#8211;/&#8211;</sup>
###xml 855 860 816 821 <italic>et al</italic>
###xml 851 866 812 827 <xref ref-type="bibr" rid="b88">Zhu <italic>et al</italic>, 2007</xref>
###xml 879 883 840 844 <italic>IRF6</italic>
###xml 1075 1080 1036 1041 <italic>et al</italic>
###xml 1069 1086 1030 1047 <xref ref-type="bibr" rid="b32">Kondo <italic>et al</italic>, 2002</xref>
###xml 1403 1431 1364 1392 <xref ref-type="bibr" rid="b12">Eroshkin and Mushegian, 1999</xref>
###xml 1552 1575 1513 1536 <xref ref-type="bibr" rid="b7">Derynck and Zhang, 2003</xref>
###xml 1577 1601 1538 1562 <xref ref-type="bibr" rid="b73">ten Dijke and Hill, 2004</xref>
###xml 1825 1833 1782 1790 <xref ref-type="fig" rid="f6">Figure 6</xref>
###xml 1970 1975 1923 1928 <italic>et al</italic>
###xml 1963 1981 1916 1934 <xref ref-type="bibr" rid="b17">Gareus <italic>et al</italic>, 2007</xref>
###xml 98 103 <span type="species:ncbi:10090">mouse</span>
###xml 181 185 <span type="species:ncbi:10090">mice</span>
###xml 268 272 <span type="species:ncbi:10090">mice</span>
###xml 873 878 <span type="species:ncbi:9606">human</span>
Other proteins may be part of the TGFbeta-Smad2/3-IKKalpha signalling pathway, as revealed by two mouse models with functional alterations of 14-3-3sigma (repeated epilation mutant mice) and IRF6, the disruption of which faithfully mimics the phenotype of Ikkalpha-/- mice (Herron et al, 2005; Li et al, 2005b; Ingraham et al, 2006; Richardson et al, 2006). 14-3-3sigma belongs to a family of adaptors that can interact with target proteins in a sequence-specific manner, although its exact function is poorly understood (Mhawech, 2005). It was reported that IKKalpha may protect the 14-3-3sigma locus from hypermethylation in keratinocytes by interacting with histone H3 (Zhu et al, 2007). In that study, the authors showed that 14-3-3sigma is downregulated in Ikkalpha-/- keratinocytes, suggesting that this gene is a downstream target of IKKalpha (Zhu et al, 2007). The human IRF6 locus is defective in Van der Woude (VWS, OMIM: 119300) and popliteal pterygium (PPS, OMIM: 11500) syndromes, which are characterized by orofacial defects such as cleft lip and palate (Kondo et al, 2002). IRF6 belongs to a family of transcription factors that share a highly conserved helix-turn-helix DNA-binding domain and a less conserved protein-binding domain. Interestingly, this protein-binding domain is related to the C-terminal MH2 domain of Smad proteins and has been referred to SMIR (Smad and IRF) domain (Eroshkin and Mushegian, 1999). As DNA binding by Smad transcription factors depends on their association with other DNA-bound transcription factors (Derynck and Zhang, 2003; ten Dijke and Hill, 2004), one can speculate that IRF6 may be a component of the Smad2/3-IKKalpha transcriptional complex that accumulates in the keratinocyte nucleus to induce the obligatory cell cycle exit that precedes terminal differentiation (Figure 6). In addition, IKKalpha may also interact with other transcription factors, such as RARs to control epidermal barrier formation (Gareus et al, 2007). The identification of other IKKalpha-interacting proteins and additional IKKalpha target genes will provide an ever better understanding of how this critical regulator of epidermal proliferation and differentiation carries out its daily work.
###end p 24
###begin p 25
###xml 46 51 <span type="species:ncbi:9606">Human</span>
This study was supported by The International Human Frontier Science Program Organization (to PD), National Institutes of Health grants (to MK) and an American Cancer Society Research Professorship (to MK).
###end p 25
###begin article-title 26
Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. 
###end article-title 26
###begin article-title 27
TAp63 and DeltaNp63 in cancer and epidermal development. 
###end article-title 27
###begin article-title 28
The cornified envelope: a model of cell death in the skin. 
###end article-title 28
###begin article-title 29
###xml 66 71 66 71 <italic>c-myc</italic>
E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. 
###end article-title 29
###begin article-title 30
###xml 4 7 <span type="species:ncbi:341683">ovo</span>
###xml 120 124 <span type="species:ncbi:10090">mice</span>
The ovo gene required for cuticle formation and oogenesis in flies is involved in hair formation and spermatogenesis in mice. 
###end article-title 30
###begin article-title 31
Targeted disruption of Smad3 reveals an essential role in transforming growth factor beta-mediated signal transduction. 
###end article-title 31
###begin article-title 32
Smad-dependent and Smad-independent pathways in TGF-beta family signalling. 
###end article-title 32
###begin article-title 33
IKKalpha is a critical coregulator of a Smad4-independent TGFbeta-Smad2/3 signaling pathway that controls keratinocyte differentiation. 
###end article-title 33
###begin article-title 34
A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. 
###end article-title 34
###begin article-title 35
Germ-layer specification and control of cell growth by Ectodermin, a Smad4 ubiquitin ligase. 
###end article-title 35
###begin article-title 36
The epidermal permeability barrier: from the early days at Harvard to emerging concepts. 
###end article-title 36
###begin article-title 37
Conserved transactivation domain shared by interferon regulatory factors and Smad morphogens. 
###end article-title 37
###begin article-title 38
Specificity and versatility in tgf-beta signaling through Smads. 
###end article-title 38
###begin article-title 39
Targeted disruption of the MYC antagonist MAD1 inhibits cell cycle exit during granulocyte differentiation. 
###end article-title 39
###begin article-title 40
The epidermis: rising to the surface. 
###end article-title 40
###begin article-title 41
Changes in keratin gene expression during terminal differentiation of the keratinocyte. 
###end article-title 41
###begin article-title 42
Normal epidermal differentiation but impaired skin-barrier formation upon keratinocyte-restricted IKK1 ablation. 
###end article-title 42
###begin article-title 43
###xml 35 40 <span type="species:ncbi:9606">human</span>
A FoxO-Smad synexpression group in human keratinocytes. 
###end article-title 43
###begin article-title 44
The Myc/Max/Mad network and the transcriptional control of cell behavior. 
###end article-title 44
###begin article-title 45
The transcription factors c-rel and RelA control epidermal development and homeostasis in embryonic and adult skin via distinct mechanisms. 
###end article-title 45
###begin article-title 46
Skin cancer's ranks rise: immunosuppression to blame. 
###end article-title 46
###begin article-title 47
Molecular pathogenesis of head and neck squamous cell carcinoma. 
###end article-title 47
###begin article-title 48
Patterned acquisition of skin barrier function during development. 
###end article-title 48
###begin article-title 49
Smads mediate signaling of the TGFbeta superfamily in normal keratinocytes but are lost during skin chemical carcinogenesis. 
###end article-title 49
###begin article-title 50
Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway. 
###end article-title 50
###begin article-title 51
###xml 84 88 <span type="species:ncbi:10090">mice</span>
A mutation in stratifin is responsible for the repeated epilation (Er) phenotype in mice. 
###end article-title 51
###begin article-title 52
Postgastrulation Smad2-deficient embryos show defects in embryo turning and anterior morphogenesis. 
###end article-title 52
###begin article-title 53
###xml 52 56 <span type="species:ncbi:10090">mice</span>
Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase. 
###end article-title 53
###begin article-title 54
IKKalpha controls formation of the epidermis independently of NF-kappaB. 
###end article-title 54
###begin article-title 55
###xml 54 58 <span type="species:ncbi:10090">mice</span>
Abnormal skin, limb and craniofacial morphogenesis in mice deficient for interferon regulatory factor 6 (Irf6). 
###end article-title 55
###begin article-title 56
Squamous cell carcinoma of the skin (excluding lip and oral mucosa). 
###end article-title 56
###begin article-title 57
Mutations in IRF6 cause Van der Woude and popliteal pterygium syndromes. 
###end article-title 57
###begin article-title 58
p63 induces key target genes required for epidermal morphogenesis. 
###end article-title 58
###begin article-title 59
Mechanisms regulating epithelial stratification. 
###end article-title 59
###begin article-title 60
Roles of TGFbeta signaling in epidermal/appendage development. 
###end article-title 60
###begin article-title 61
Role of TGFbeta in skin inflammation and carcinogenesis. 
###end article-title 61
###begin article-title 62
Current view of the role of transforming growth factor beta 1 in skin carcinogenesis. 
###end article-title 62
###begin article-title 63
###xml 98 103 <span type="species:ncbi:10090">mouse</span>
Identification of 14-3-3sigma mutation causing cutaneous abnormality in repeated-epilation mutant mouse. 
###end article-title 63
###begin article-title 64
###xml 15 19 <span type="species:ncbi:10090">mice</span>
IKK1-deficient mice exhibit abnormal development of skin and skeleton. 
###end article-title 64
###begin article-title 65
###xml 29 33 <span type="species:ncbi:10090">mice</span>
Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. 
###end article-title 65
###begin article-title 66
The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. 
###end article-title 66
###begin article-title 67
###xml 64 69 <span type="species:ncbi:9606">human</span>
###xml 74 79 <span type="species:ncbi:10090">mouse</span>
A critical role for I kappaB kinase alpha in the development of human and mouse squamous cell carcinomas. 
###end article-title 67
###begin article-title 68
###xml 46 51 <span type="species:ncbi:10090">mouse</span>
Development and morphology of the periderm of mouse embryos (days 9-12 of gestation). 
###end article-title 68
###begin article-title 69
Epigenetic inactivation of IkappaB Kinase-alpha in oral carcinomas and tumor progression. 
###end article-title 69
###begin article-title 70
How cells read TGF-beta signals. 
###end article-title 70
###begin article-title 71
TGFbeta signaling in growth control, cancer, and heritable disorders. 
###end article-title 71
###begin article-title 72
IKK-1 and IKK-2: cytokine-activated IkappaB kinases essential for NF-kappaB activation. 
###end article-title 72
###begin article-title 73
14-3-3 proteins-an update. 
###end article-title 73
###begin article-title 74
###xml 18 23 <span type="species:ncbi:9606">human</span>
IKKalpha enhances human keratinocyte differentiation and determines the histological variant of epidermal squamous cell carcinomas. 
###end article-title 74
###begin article-title 75
###xml 88 93 88 93 <italic>c-myc</italic>
Ovol1 regulates the growth arrest of embryonic epidermal progenitor cells and represses c-myc transcription. 
###end article-title 75
###begin article-title 76
Smad2 role in mesoderm formation, left-right patterning and craniofacial development. 
###end article-title 76
###begin article-title 77
TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis. 
###end article-title 77
###begin article-title 78
TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. 
###end article-title 78
###begin article-title 79
The role of Smads in skin development. 
###end article-title 79
###begin article-title 80
Reduction in IkappaB kinase alpha expression promotes the development of skin papillomas and carcinomas. 
###end article-title 80
###begin article-title 81
###xml 90 95 <span type="species:ncbi:10090">mouse</span>
Hair follicle defects and squamous cell carcinoma formation in Smad4 conditional knockout mouse skin. 
###end article-title 81
###begin article-title 82
Identification and characterization of an IkappaB kinase. 
###end article-title 82
###begin article-title 83
Irf6 is a key determinant of the keratinocyte proliferation-differentiation switch. 
###end article-title 83
###begin article-title 84
Histologic variants of squamous cell carcinoma of the skin. 
###end article-title 84
###begin article-title 85
IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. 
###end article-title 85
###begin article-title 86
Id proteins: novel targets of activin action, which regulate epidermal homeostasis. 
###end article-title 86
###begin article-title 87
Squamous cell carcinoma of the skin. 
###end article-title 87
###begin article-title 88
TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. 
###end article-title 88
###begin article-title 89
Epidermal barrier formation and recovery in skin disorders. 
###end article-title 89
###begin article-title 90
Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. 
###end article-title 90
###begin article-title 91
Mechanisms of TGF-beta signaling from cell membrane to the nucleus. 
###end article-title 91
###begin article-title 92
Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. 
###end article-title 92
###begin article-title 93
IkappaB kinase-alpha acts in the epidermis to control skeletal and craniofacial morphogenesis. 
###end article-title 93
###begin article-title 94
Demographics and occurrence of oral and pharyngeal cancers. The outcomes, the trends, the challenge. 
###end article-title 94
###begin article-title 95
###xml 84 89 <span type="species:ncbi:10090">mouse</span>
Variation in the plane of cell cleavage during the process of stratification in the mouse epidermis. 
###end article-title 95
###begin article-title 96
###xml 31 35 <span type="species:ncbi:10090">mice</span>
Limb and skin abnormalities in mice lacking IKKalpha. 
###end article-title 96
###begin article-title 97
###xml 98 102 <span type="species:ncbi:10090">mice</span>
Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice. 
###end article-title 97
###begin article-title 98
New insights into TGF-beta-Smad signalling. 
###end article-title 98
###begin article-title 99
###xml 55 62 55 62 <italic>in vivo</italic>
###xml 97 105 97 105 <italic>in vitro</italic>
Expression of the mad gene during cell differentiation in vivo and its inhibition of cell growth in vitro. 
###end article-title 99
###begin article-title 100
###xml 94 99 <span type="species:ncbi:10090">mouse</span>
Smad2 signaling in extraembryonic tissues determines anterior-posterior polarity of the early mouse embryo. 
###end article-title 100
###begin article-title 101
MYC in mammalian epidermis: how can an oncogene stimulate differentiation?
###end article-title 101
###begin article-title 102
###xml 61 66 <span type="species:ncbi:10090">mouse</span>
Failure of egg cylinder elongation and mesoderm induction in mouse embryos lacking the tumor suppressor smad2. 
###end article-title 102
###begin article-title 103
###xml 119 124 <span type="species:ncbi:10090">mouse</span>
Embryology of the epidermis: ultrastructural aspects. III. Maturation and primary appearance of dendritic cells in the mouse with mammalian comparisons. 
###end article-title 103
###begin article-title 104
The Mad1 transcription factor is a novel target of activin and TGF-beta action in keratinocytes: possible role of Mad1 in wound repair and psoriasis. 
###end article-title 104
###begin article-title 105
IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK. 
###end article-title 105
###begin article-title 106
Complementation cloning of NEMO, a component of the IkappaB kinase complex essential for NF-kappaB activation. 
###end article-title 106
###begin article-title 107
###xml 32 37 <span type="species:ncbi:10090">mouse</span>
Targeted disruption of Smad4 in mouse epidermis results in failure of hair follicle cycling and formation of skin tumors. 
###end article-title 107
###begin article-title 108
Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. 
###end article-title 108
###begin article-title 109
IkappaB kinase alpha is essential for development of the mammalian cornea and conjunctiva. 
###end article-title 109
###begin article-title 110
The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. 
###end article-title 110
###begin article-title 111
NF-kappaB RelA opposes epidermal proliferation driven by TNFR1 and JNK. 
###end article-title 111
###begin article-title 112
IKKalpha shields 14-3-3sigma, a G(2)/M cell cycle checkpoint gene, from hypermethylation, preventing its silencing. 
###end article-title 112
###begin article-title 113
###xml 13 17 <span type="species:ncbi:10090">mice</span>
Smad3 mutant mice develop metastatic colorectal cancer. 
###end article-title 113
###begin p 114
###xml 37 40 37 40 <italic>Ikk</italic>
###xml 45 48 41 44 <sup>&#8211;/&#8211;</sup>
###xml 49 53 <span type="species:ncbi:10090">mice</span>
Macroscopical presentation of WT and Ikkalpha-/- mice.
###end p 114
###begin p 115
###xml 1 2 1 2 <bold>A</bold>
###xml 65 68 65 68 <italic>Ikk</italic>
###xml 73 76 69 72 <sup>&#8211;/&#8211;</sup>
###xml 84 85 80 81 <bold>B</bold>
###xml 126 129 122 125 <italic>Ikk</italic>
###xml 298 313 290 305 <italic>stratum corneum</italic>
###xml 77 81 <span type="species:ncbi:10090">mice</span>
(A) Haematoxylin and eosin staining of skin sections from WT and Ikkalpha-/- mice. (B) Schematic representation of normal and Ikkalpha-deficient epidermis with expression profile of molecular markers of proliferation and differentiation (BL: basal layer; SP: spinous layer; GR: granular layer; SC: stratum corneum; hf: hair follicle; de: dermis; magnification x 100 in (A)).
###end p 115
###begin p 116
Schematic representation of epidermal development stages. We propose that the main function of IKKalpha is to induce cell cycle exit of intermediate keratinocytes when they mature into spinous cells.
###end p 116
###begin p 117
###xml 112 116 105 109 <italic>Mad1</italic>
###xml 121 127 114 120 <italic>Ovol 1</italic>
###xml 486 491 469 474 <italic>c-Myc</italic>
###xml 526 531 509 514 <italic>et al</italic>
###xml 521 537 504 520 <xref ref-type="bibr" rid="b4">Chen <italic>et al</italic>, 2002</xref>
TGFbeta-related signalling pathway controlling Myc activity in keratinocytes. The IKKalpha-Smad2/3 axis induces Mad1 and Ovol 1 expression on TGFbeta stimulation. These proteins may inhibit the activity and expression of Myc, inducing in turn keratinocyte cycle exit and differentiation. Interestingly, a TGFbeta-Smad3/4 signalling pathway, which is not associated with IKKalpha, but functions in cooperation with E2F4/5 transcription factors, has also been shown to negatively control c-Myc expression in keratinocytes (Chen et al, 2002).
###end p 117
###begin p 118
###xml 161 166 161 166 <italic>et al</italic>
###xml 158 172 158 172 <xref ref-type="bibr" rid="b29">Hu <italic>et al</italic>, 2001</xref>
###xml 211 214 211 214 <italic>Ikk</italic>
###xml 219 222 215 218 <sup>&#8211;/&#8211;</sup>
###xml 359 362 351 354 <italic>Ikk</italic>
###xml 367 370 355 358 <sup>&#8211;/&#8211;</sup>
Mad1 expression is not induced by kDIF-mediated keratinocyte differentiation. Conditioned medium from WT keratinocytes, which contains kDIF as shown earlier (Hu et al, 2001), failed to induce Mad1 expression in Ikkalpha-/- keratinocytes while leading to keratinocyte differentiation as indicated by filaggrin expression. Only the re-expression of IKKalpha in Ikkalpha-/- keratinocytes infected with adenovirus encoding this protein (Ad-IKKalpha) induces Mad1 expression.
###end p 118
###begin p 119
###xml 1 2 1 2 <bold>A</bold>
###xml 432 433 426 427 <bold>B</bold>
###xml 725 729 712 716 <italic>Mad1</italic>
###xml 734 739 721 726 <italic>Ovol1</italic>
(A) In the canonical TGFbeta signalling pathway, ligands signal through type I and II transmembrane protein kinase receptors. After TGFbeta binding, type II receptor recruits and phosphorylates type I receptor, which in turn activates R-Smads. Phosphorylated R-Smads oligomerize with the co-Smad Smad4 and accumulate in the nucleus where they interact with DNA and transcription factors to regulate the expression of target genes. (B) During epidermal terminal differentiation, TGFbeta1 stimulation of keratinocytes induces the formation of a complex between activated Smad2/3 and IKKalpha. This complex accumulates in keratinocyte nuclei independently of the presence of Smad4 and controls the transcriptional activation of Mad1 and Ovol1 probably with the cooperation of other transcription factors such as IRF6. The Smad4-independent TGFbeta-Smad2/3-IKKalpha axis is required for cell cycle exit and induction of terminal differentiation of keratinocytes.
###end p 119

